MOR - MorphoSys HIBio enter into licensing agreements for two of MorphoSys' antibodies

MorphoSys (NASDAQ:MOR) and U.S. biotech Human Immunology Bioscience (HIBio) have entered into licensing agreements to allow HIBio to develop and commercialize two of MorphoSys' antibodies. The antibodies are MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody, the German biopharma company said in a statement on Tuesday. As per the deals, HIBio will get exclusive worldwide rights, with the exception of Greater China, for felzartamab, and Greater China and South Korea for MOR210. MOR will get a 15% equity stake in HIBio and up to $1B in milestone payments across programs, plus single- to low double-digit royalties on net sales. It will also get an upfront payment of $15M for MOR210. U.S.-listed shares of MorphoSys earlier closed -1.5% at $4.56.

For further details see:

MorphoSys, HIBio enter into licensing agreements for two of MorphoSys' antibodies